Inventor · disambiguated record
John S. Kovach
Also filed as: KOVACH JOHN · KOVACH JOHN S
31 granted patents·21 pending applications·369 citations·filing 1989–2024
97Inventor score
Files withLIXTE BIOTECHNOLOGY INC23KOVACH JOHN S19H LEE MOFFITT CANCER CT & RES2HOPE CITY1JOHN S KOVACH1
Top patents by PatentIndex Score
52 records- 0198US11236102B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2020·Granted Feb 1, 2022·5 cites·9 claims
- 0296US10618908B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2019·Granted Apr 14, 2020·6 cites·11 claims
- 0396US8058268B2Neuroprotective agents for the prevention and treatment of neurodegenerative diseasesKOVACH JOHN S·Filed 2009·Granted Nov 15, 2011·46 cites·6 claims
- 0496US7998957B2Oxabicycloheptanes and oxabicylcoheptenes, their preparation and useLIXTE BIOTECHNOLOGY INC·Filed 2008·Granted Aug 16, 2011·39 cites·30 claims
- 0595US10364252B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2018·Granted Jul 30, 2019·7 cites·19 claims
- 0695US9988394B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2016·Granted Jun 5, 2018·7 cites·16 claims
- 0795US9526915B2Methods for regulating cell mitosis by inhibiting serine/threonine phosphataseKOVACH JOHN S·Filed 2013·Granted Dec 27, 2016·15 cites·25 claims
- 0893US10668062B2Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetesLIXTE BIOTECHNOLOGY INC·Filed 2018·Granted Jun 2, 2020·5 cites·20 claims
- 0993US9079917B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useLIXTE BIOTECHNOLOGY INC·Filed 2014·Granted Jul 14, 2015·17 cites·26 claims
- 1093US8822461B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useLIXTE BIOTECHNOLOGY INC·Filed 2013·Granted Sep 2, 2014·16 cites·20 claims
- 1193US8227473B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useKOVACH JOHN S·Filed 2009·Granted Jul 24, 2012·26 cites·11 claims
- 1292US11866444B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2022·Granted Jan 9, 2024·1 cites·10 claims
- 1392US8143445B2HDAC inhibitorsKOVACH JOHN S·Filed 2008·Granted Mar 27, 2012·22 cites·49 claims
- 1491US10023587B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useLIXTE BIOTECHNOLOGY INC·Filed 2017·Granted Jul 17, 2018·6 cites·3 claims
- 1591US8541458B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useKOVACH JOHN S·Filed 2012·Granted Sep 24, 2013·17 cites·9 claims
- 1691US8329719B2Neuroprotective agents for the prevention and treatment of neurodegenerative diseasesKOVACH JOHN S·Filed 2011·Granted Dec 11, 2012·16 cites·9 claims
- 1790US8455688B2HDAC inhibitorsKOVACH JOHN S·Filed 2012·Granted Jun 4, 2013·14 cites·20 claims
- 1890US8426444B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useKOVACH JOHN·Filed 2011·Granted Apr 23, 2013·21 cites·20 claims
- 1989US10399993B2Oxabicycloheptanes and oxabicycloheptenes, their preparation and useLIXTE BIOTECHNOLOGY INC·Filed 2018·Granted Sep 3, 2019·5 cites·14 claims
- 2089US10149847B2Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetesLIXTE BIOTECHNOLOGY INC·Filed 2013·Granted Dec 11, 2018·6 cites·20 claims
- 2189US9833450B2Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disordersKOVACH JOHN S·Filed 2016·Granted Dec 5, 2017·9 cites·20 claims
- 2286US10413541B2Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disordersLIXTE BIOTECHNOLOGY INC·Filed 2017·Granted Sep 17, 2019·5 cites·20 claims
- 2386US10071094B2Protein phosphatase 2A inhibitors for treating myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2015·Granted Sep 11, 2018·7 cites·19 claims
- 2484US10434100B2Protein phosphatase 2A inhibitors for treating myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Oct 8, 2019·5 cites·20 claims
- 2581US11931354B2Formulations of oxabicycloheptanes and oxabicycloheptenesLIXTE BIOTECHNOLOGY INC·Filed 2019·Granted Mar 19, 2024·1 cites·4 claims
- 2679US10532050B2Formulations of oxabicycloheptanes and oxabicycloheptenesLIXTE BIOTECHNOLOGY INC·Filed 2014·Granted Jan 14, 2020·5 cites·12 claims
- 2778US12343342B2Methods for treating soft tissue sarcomaLIXTE BIOTECHNOLOGY INC·Filed 2023·Granted Jul 1, 2025·0 cites·5 claims
- 2866US2025221985A1Oxabicycloheptanes for Modulation of Immune ResponseLIXTE BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 2961US6406429B1Detection of cystic structures using pulsed ultrasonically induced resonant cavitationHOPE CITY·Filed 2000·Granted Jun 18, 2002·16 cites·14 claims
- 3061US2023310418A1Compositions and methods for treating cancer or preventing, inhibiting or reducing risk of metastasis of a cancerLIXTE BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 3160US2009035292A1Use of phosphatases to treat neuroblastomas and medulloblastomasKOVACH JOHN S·Filed 2008·Application pending·0 cites
- 3259US8478534B2Method for detecting discriminatory data patterns in multiple sets of data and diagnosing diseaseZHU WEI·Filed 2004·Granted Jul 2, 2013·9 cites·26 claims
- 3359US2016009727A1Sanguinarine analog pp2c inhibitors for cancer treatmentKOVACH JOHN S·Filed 2014·Application pending·0 cites
- 3458US2023065158A1Oxabicycloheptanes for treatment of small cell lung cancerLIXTE BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3557US2022323433A2Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitorLIST ALAN F·Filed 2022·Application pending·0 cites
- 3653US12168008B2Oxabicycloheptanes for modulation of immune responseLIXTE BIOTECHNOLOGY INC·Filed 2017·Granted Dec 17, 2024·0 cites·35 claims
- 3753US2017259081A1Methods for regulating cell mitosis by inhibiting serine/threonine phosphataseKOVACH JOHN S·Filed 2016·Application pending·0 cites
- 3853US2017240558A1Sanguinarine analog pp2c inhibitors for cancer treatmentKOVACH JOHN S·Filed 2017·Application pending·0 cites
- 3953US2019111053A1Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitorLIXTE BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 4051US2021275521A1Oxabicycloheptanes for treatment of secondary acute myeloid leukemiaLIXTE BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 4151US2010029683A1Methods for regulating cell mitosis by inhibiting serine/threonine phosphatesesKOVACH JOHN S·Filed 2009·Application pending·0 cites
- 4251US2021379106A1Oxabicycloheptanes for enhancing car t cell functionLIXTE BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 4350US5004593AHexamethylmelamine formulation exhibiting reduced neurotoxicityMAYO FOUNDATION·Filed 1989·Granted Apr 2, 1991·15 cites·7 claims
- 4447US2013238251A1Method and system for detecting discriminatory data patterns in multiple sets of dataUNIV NEW YORK STATE RES FOUND·Filed 2013·Application pending·0 cites
- 4546US2016264593A1Protein phosphatase inhibitors that cross the blood brain barrierKOVACH JOHN S·Filed 2014·Application pending·0 cites
- 4645US2016008336A1Hdac inhibitors for the treatment of traumatic brain injuryKOVACH JOHN S·Filed 2014·Application pending·0 cites
- 4744US2009018142A9Use of phosphatases to treat tumors overexpressing N-CoRZHUANG ZHENGPING·Filed 2007·Application pending·0 cites
- 4843US2015174123A1Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injuryJOHN S KOVACH·Filed 2013·Application pending·0 cites
- 4940US2014235649A1Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein functionKOVACH JOHN S·Filed 2012·Application pending·0 cites
- 5039US2012135522A1Methods of modulating cell regulation by inhibiting p53KOVACH JOHN S·Filed 2010·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John S. Kovach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →